| Abacus Global Management riding wave of life settlements growth after Q1 earnings beat |
Abacus Global Management (NASDAQ:ABL) is quickly proving its mettle in the alternative asset management space, delivering strong first-quarter earnings that exceeded Wall Street expectations and showcased the firm's growing dominance in life settlements and adjacent financial services. The company posted adjusted earnings per share (EPS) of $0.18 for the first quarter of fiscal 2025, beating consensus estimates of $0.16 and driven by record capital deployment and strong performance in its Life Solutions and Asset Management businesses. |
proactiveinvestors.com |
2025-05-15 19:43:51 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 |
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations |
globenewswire.com |
2025-05-14 13:30:00 |
Czytaj oryginał (ang.) |
| Abacus Life, Inc. (ABL) Upgraded to Buy: Here's Why |
Abacus Life, Inc. (ABL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-05-13 17:00:42 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 57.47% Upside in Abacus Life, Inc. (ABL): Here's What You Should Know |
The consensus price target hints at a 57.5% upside potential for Abacus Life, Inc. (ABL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-05-13 15:01:19 |
Czytaj oryginał (ang.) |
| Is Abacus Life, Inc. (ABL) Outperforming Other Finance Stocks This Year? |
Here is how Abacus Life, Inc. (ABL) and Annaly Capital Management (NLY) have performed compared to their sector so far this year. |
zacks.com |
2025-05-13 14:46:23 |
Czytaj oryginał (ang.) |
| Abacus Global Management Announces Virtual Livestream Details for the Abacus Investor Day and Longevity Summit on Thursday, June 12th, 2025 |
ORLANDO, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leader in the alternative asset management space, today announced details for the virtual livestream of the Abacus Investor Day and Longevity Summit to be held on Thursday, June 12, 2025, beginning at 9:30AM ET. |
globenewswire.com |
2025-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Abacus Global Management, Inc. (ABL) Q1 2025 Earnings Call Transcript |
Abacus Global Management, Inc. (NASDAQ:ABL ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Robert Phillips - Senior Vice President-Investor Relations & Corporate Affairs Jay Jackson - Chairman & Chief Executive Officer Bill McCauley - Chief Financial Officer Conference Call Participants Patrick Davitt - Autonomous Research Crispin Love - Piper Sandler Randy Binner - B. Riley Andrew Kligerman - TD Securities Mike Grondahl - Northland Securities Operator Greetings, and welcome to the Abacus Global Management First Quarter 2025 Earnings Call. |
seekingalpha.com |
2025-05-09 22:10:49 |
Czytaj oryginał (ang.) |
| Abacus Life, Inc. (ABL) Q1 Earnings and Revenues Top Estimates |
Abacus Life, Inc. (ABL) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.11 per share a year ago. |
zacks.com |
2025-05-08 23:40:38 |
Czytaj oryginał (ang.) |
| Abacus Global Management doubles revenue, adjusted earnings in Q1 on strong asset inflows |
Abacus Global Management (NASDAQ:ABL) more than doubled its revenue and adjusted earnings in the first quarter of 2025, driven by increased capital deployment and rising demand for alternative assets, the company said on Thursday. The New York-based asset manager posted total revenue of $44.1 million for the quarter ended March 31, up from $21.5 million a year earlier, fueled by gains in its Life Solutions business and a full quarter of fees from acquisitions completed late last year. |
proactiveinvestors.com |
2025-05-08 20:36:33 |
Czytaj oryginał (ang.) |
| Abacus Global Management Reports First Quarter 2025 Results |
– First Quarter 2025 Total Revenue More Than Doubled Year-over-Year to $44.1 Million – - Longevity Funds Attracted $122.8 Million in Capital Inflows - – GAAP Net Income of $4.6 Million – – Adjusted Net Income Grew 158% Year-over-Year to $17.3 Million – – Adjusted EBITDA More Than Doubled Year-over-Year to $24.5 Million – ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leader in the alternative asset management space, today reported results for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-08 20:15:00 |
Czytaj oryginał (ang.) |
| Abacus Life, Inc. (ABL) Reports Next Week: Wall Street Expects Earnings Growth |
Abacus Life, Inc. (ABL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:06:07 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in Abacus Life Stock? |
Investors need to pay close attention to ABL stock based on the movements in the options market lately. |
zacks.com |
2025-04-24 13:35:38 |
Czytaj oryginał (ang.) |
| Abacus Global Management sees increased demand as market volatility boosts interest in alternative funds |
Abacus Global Management (NASDAQ:ABL) has highlighted that it remains well-positioned to benefit from ongoing market volatility, citing structural strengths in its business model and continued demand for alternative investments. The company, which operates in the alternative asset management sector, said it has seen a rise in origination and investor interest as traditional markets remain turbulent. |
proactiveinvestors.com |
2025-04-07 20:34:55 |
Czytaj oryginał (ang.) |
| Abacus Global Management Well-Positioned Amid Market Volatility |
ORLANDO, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management (“Abacus” or the “Company”) (NASDAQ: ABL), a leader in the alternative asset management space, commented on the ongoing macro environment, noting that it remains well-positioned to capitalize on current market volatility, according to Chairman and Chief Executive Officer Jay Jackson. The Company's unique business model provides it with clear strategic advantages in uncertain market conditions. |
globenewswire.com |
2025-04-07 20:15:00 |
Czytaj oryginał (ang.) |
| Abacus Global Management transforms life insurance as an alternative asset class |
Life insurance is often seen as a safety net — a financial cushion for loved ones after a policyholder's death. But for those who understand its true value, life insurance can also serve as a unique and underutilized asset class, offering opportunities for investment and financial planning far beyond its intended purpose. |
proactiveinvestors.com |
2025-04-07 14:04:54 |
Czytaj oryginał (ang.) |
| ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases |
- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectively deliver molecules a cross the blood-brain barrier - ABL Bio to receive up to £77 million in upfront and near-term payments SEONGNAM, South Korea , April 6, 2025 /PRNewswire/ -- ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B. The agreement aims to develop multiple programs for novel targets across therapeutic modalities including antibody, polynucleotide or oligonucleotides, such as siRNA and ASOs, to address significant unmet medical needs of patients suffering from neurodegenerative conditions. |
prnewswire.com |
2025-04-07 00:03:00 |
Czytaj oryginał (ang.) |
| Abacus Global Management sees revenue surge in 2024 – ICYMI |
Abacus Global Management (NASDAQ:ABL) earlier this week told investors it expects adjusted net income to grow by between 51% and 68% in 2025. The company reported full-year 2024 revenue growth of 69% year-over-year. |
proactiveinvestors.com |
2025-04-04 19:22:02 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 76.37% Upside in Abacus Life, Inc. (ABL): Can the Stock Really Move This High? |
The mean of analysts' price targets for Abacus Life, Inc. (ABL) points to a 76.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-04-03 14:55:40 |
Czytaj oryginał (ang.) |
| 4 Stocks to Watch From a Prospering Life Insurance Industry |
Redesigning and repricing of products and services amid a low rate environment are likely to help Zacks Life Insurance industry players like AVVIY, NNGRY, JXN and ABL. These companies are investing heavily in digitization. |
zacks.com |
2025-04-01 17:36:07 |
Czytaj oryginał (ang.) |
| Abacus Life, Inc. (ABL) Q4 2024 Earnings Conference Call Transcript |
Abacus Life, Inc. (NASDAQ:ABL ) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Robert Phillips - SVP, IR and Corporate Affairs Jay Jackson - Chairman and CEO Bill McCauley - CFO Conference Call Participants Patrick Davitt - Autonomous Research Crispin Love - Piper Sandler Randy Binner - B. Riley Securities Mike Grondahl - Northland Securities Andrew Kligerman - TD Securities Operator Good day, ladies and gentlemen, and thank you for standing by. |
seekingalpha.com |
2025-03-27 22:44:33 |
Czytaj oryginał (ang.) |
| Abacus Life gains analyst support as it expands asset management business |
Abacus Life Inc (NASDAQ:ABL) is gaining traction among analysts as it transitions from a life settlements firm into a broader asset management player. Analysts at Autonomous Research, Northland, and Piper Sandler see the alternative asset management company as significantly undervalued, with a strong market position, growing revenue streams, and potential for valuation upside. |
proactiveinvestors.com |
2025-02-27 17:43:05 |
Czytaj oryginał (ang.) |
| Abacus Life to Announce Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 |
ORLANDO, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, today announced it will release its fourth quarter 2024 financial results after the market closes on Thursday, March 27, 2025. |
globenewswire.com |
2025-02-25 10:00:00 |
Czytaj oryginał (ang.) |
| Abacus Life Announces Private Exchange of Outstanding Public Warrants |
ORLANDO, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in leveraging longevity and actuarial technology to offer uncorrelated investment opportunities, today announced that it has entered into warrant exchange agreements (each, an “Exchange Agreement”) with certain holders (the “Holders”) of its outstanding publicly traded warrants (the “Public Warrants”) to purchase shares of the Company's common stock, par value $0.0001 per share (“Common Stock”). Pursuant to their respective Exchange Agreements, the Holders agreed to surrender an aggregate of 4,930,745 Public Warrants in exchange for an aggregate of 1,134,071 shares of newly issued Common Stock, representing a ratio of 0.23 shares per warrant.1 |
globenewswire.com |
2025-02-24 10:34:00 |
Czytaj oryginał (ang.) |
| Abacus Life rebrands FCF Advisors, launches new small-cap ETF |
Abacus Life Inc (NASDAQ:ABL) said on Wednesday it has rebranded FCF Advisors as Abacus FCF Advisors, a subsidiary of ABL Wealth, as part of its expansion into free cash flow-focused investment strategies. As part of the transition, Abacus FCF Advisors launched the Abacus FCF Small Cap Leaders ETF (ABLS) and announced management fee reductions of five to 10 basis points across all its ETFs. |
proactiveinvestors.com |
2025-02-19 11:00:27 |
Czytaj oryginał (ang.) |
| Abacus Life Completes the Rebranding of FCF Advisors with New ETF and Fee Reductions |
ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, today announces the rebranding of FCF Advisors to Abacus FCF Advisors, a subsidiary of ABL Wealth. |
globenewswire.com |
2025-02-19 10:00:00 |
Czytaj oryginał (ang.) |
| Acuity Brands Inc.: Stay Bullish As Growth Should Turn Better |
I maintain a buy rating on Acuity Brands Inc. due to strong growth prospects in both ABL and ISG segments, supported by positive demand indicators. 1Q25 results showed 2% y/y revenue growth to $952 million, driven by ABL's stable performance and ISG's 15% y/y growth, with notable margin expansion. Easing interest rates and a robust non-residential construction pipeline, evidenced by the Dodge Momentum Index, bolster ABL's growth outlook for FY25. |
seekingalpha.com |
2025-01-12 02:17:17 |
Czytaj oryginał (ang.) |
| NN, Inc. Announces New Asset-Based Lending Facility |
New ABL facility marks successful next step in Company's balance sheet optimization strategy New ABL facility marks successful next step in Company's balance sheet optimization strategy |
globenewswire.com |
2025-01-02 18:15:00 |
Czytaj oryginał (ang.) |
| Abacus Life, Inc. (ABL) Upgraded to Strong Buy: Here's What You Should Know |
Abacus Life, Inc. (ABL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-26 15:01:18 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Abacus Life, Inc. (ABL) Could Surge 86.27%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 86.3% in Abacus Life, Inc. (ABL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-12-23 12:56:06 |
Czytaj oryginał (ang.) |
| Abacus Life Completes Acquisition of FCF Advisors |
ORLANDO, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, today announced it has completed the acquisition of FCF Advisors (“FCF”), a New York-based asset manager and index provider specializing in free cash flow-focused investment strategies. The acquisition of FCF, which currently has approximately $850 million in assets under management, constitutes a significant milestone in Abacus' ongoing expansion of ABL Wealth and its suite of products. |
globenewswire.com |
2024-12-02 18:01:00 |
Czytaj oryginał (ang.) |
| Abacus Life Completes Acquisition of Carlisle Management Company S.C.A. |
ORLANDO, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, today announced it has completed the acquisition of Carlisle Management Company S.C.A. (“Carlisle”), a leading Luxembourg-based investment fund manager in the life settlement space with over U.S. $2 billion in assets under management. The Carlisle acquisition marks a key milestone in Abacus's stated strategy to drive long-term growth and diversify its value proposition through expanded global alternative asset-management offerings. |
globenewswire.com |
2024-12-02 12:38:00 |
Czytaj oryginał (ang.) |
| Abacus Life Targets Close of the Acquisition of Carlisle Management Company S.C.A. for December 2, 2024 with Receipt of Regulatory Non-Objection |
ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, announced it has received regulatory non-objection from the Luxembourg Commission de Surveillance du Secteur Financier (“CSSF”) for the acquisition of Carlisle Management Company S.C.A. (“Carlisle”), a leading Luxembourg-based investment fund manager in the life settlement space. |
globenewswire.com |
2024-11-26 11:48:00 |
Czytaj oryginał (ang.) |
| Abacus Life Announces Closing of Public Offering of 12,500,000 Shares of Common Stock |
ORLANDO, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, today announced the closing of its oversubscribed underwritten public offering of 12,500,000 shares of its common stock, consisting of 10,000,000 shares of its common stock sold by the Company and 2,500,000 shares of common stock sold by certain stockholders of the Company (the “Selling Stockholders”) at the public offering price of $8.00 per share. The gross proceeds raised in the offering, before underwriting discounts and commissions and estimated expenses of the offering, were approximately $100 million, of which approximately $80 million was raised in the primary offering by the Company and approximately $20 million was paid in connection with the sale of shares by the Selling Stockholders. |
globenewswire.com |
2024-11-25 19:23:00 |
Czytaj oryginał (ang.) |
| Abacus Life's CEO on Cracking the Code of Longevity Returns |
Abacus Life, Inc. NASDAQ: ABL is a global alternative asset manager specializing in a unique niche within the financial markets. The company acquires and manages life insurance policies. |
marketbeat.com |
2024-11-25 16:49:05 |
Czytaj oryginał (ang.) |
| Abacus Life Announces Pricing of Public Offering of Common Stock |
ORLANDO, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock, including 10,000,000 shares of common stock being offered by the Company and 2,500,000 shares of common stock being offered by certain stockholders of the Company (the “Selling Stockholders”), at a price to the public of $8.00 per share. In connection with the offering, the Company also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock from the Company and up to an additional 375,000 shares of common stock from the Selling Stockholders at the public offering price. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $100 million, excluding any exercise of the underwriters' option to purchase additional shares. |
globenewswire.com |
2024-11-21 21:25:00 |
Czytaj oryginał (ang.) |
| Abacus Life Announces Proposed Public Offering of Common Stock |
ORLANDO, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in leveraging longevity and actuarial technology to offer uncorrelated investment opportunities, today announced the commencement of an underwritten public offering of 12,500,000 shares of its common stock, including 10,000,000 shares of common stock to be sold by the Company and 2,500,000 to be sold by certain stockholders of the Company (the “Selling Stockholders”). The Company and the Selling Stockholders also expect to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock from the Company and up to an additional 375,000 shares of common stock from the Selling Stockholders. |
globenewswire.com |
2024-11-21 18:01:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Abacus Life, Inc. (ABL) Could Rally 59.48%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 59.5% in Abacus Life, Inc. (ABL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-21 12:56:24 |
Czytaj oryginał (ang.) |
| Abacus Life, Inc. (ABL) Q3 2024 Earnings Call Transcript |
Abacus Life, Inc. (NASDAQ:ABL ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Robert Phillips – Senior Vice President- Investor Relations and Corporate Affairs Jay Jackson – Chairman and Chief Executive Officer Bill McCauley – Chief Financial Officer Conference Call Participants Crispin Love – Piper Sandler Andrew Kligerman – TD Cowen Mike Grondahl – Northland Securities Operator Good day, ladies and gentlemen, and thank you for standing by. At this time all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-09 07:15:28 |
Czytaj oryginał (ang.) |
| Abacus Life, Inc. (ABL) Surpasses Q3 Earnings and Revenue Estimates |
Abacus Life, Inc. (ABL) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.01 per share a year ago. |
zacks.com |
2024-11-07 22:11:13 |
Czytaj oryginał (ang.) |
| Abacus Life Reports Third Quarter 2024 Results |
- Delivered Continued Revenue and Profitability Growth While Executing on Strategic Initiatives - - Third Quarter 2024 Total Revenue Grows 33% Year-over-Year to $28.1 Million - - Due to Non-Cash Increase in Warrant Liability of $8.7M; GAAP Net Loss of $5.1M - - Adjusted Net Income Grows 65% Year-over-Year to $14.9 Million - - Adjusted EBITDA Grows 54% Year-over-Year to $16.7 Million - ORLANDO, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, today reported results for the third quarter ended September 30, 2024. |
globenewswire.com |
2024-11-07 18:15:00 |
Czytaj oryginał (ang.) |
| Abacus Life, Inc. (ABL) Earnings Expected to Grow: Should You Buy? |
Abacus Life, Inc. (ABL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-31 13:07:17 |
Czytaj oryginał (ang.) |
| Cambridge Savings Bank Extends New Credit Facility to Accelerate Growth for Fabrizia Spirits |
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #SMBs--Cambridge Savings Bank has provided a new credit facility to Fabrizia Spirits, a leading citrus spirits manufacturer in the United States. |
businesswire.com |
2024-10-17 14:08:00 |
Czytaj oryginał (ang.) |
| Abacus Life to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024 |
ORLANDO, Fla., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leading global alternative asset manager focused on lifespan-based financial products, today announced it will release its Third Quarter 2024 financial results after the market closes on Thursday, November 7, 2024. |
globenewswire.com |
2024-10-11 13:00:00 |
Czytaj oryginał (ang.) |
| What Makes Abacus Life, Inc. (ABL) a Strong Momentum Stock: Buy Now? |
Does Abacus Life, Inc. (ABL) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-09-24 17:02:18 |
Czytaj oryginał (ang.) |
| Buy 4 Low-Beta Stocks & Forget About Volatility: ERIE, SFM, AVO, ABL |
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. ERIE, SFM, AVO & ABL are well-poised to gain. |
zacks.com |
2024-09-19 19:46:07 |
Czytaj oryginał (ang.) |
| Strength Seen in Abacus Life, Inc. (ABL): Can Its 5.4% Jump Turn into More Strength? |
Abacus Life, Inc. (ABL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
zacks.com |
2024-09-19 16:16:11 |
Czytaj oryginał (ang.) |